Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

BACKGROUND: The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement findings from the pivotal program, this observational study was designed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gantenbein, Andreas R., Agosti, Reto, Kamm, Christian P., Landmann, Gunther, Meier, Niklaus, Merki-Feld, Gabriele Susanne, Petersen, Jens A., Pohl, Heiko, Ryvlin, Philippe, Schankin, Christoph J., Viceic, Dragana, Zecca, Chiara, Schäfer, Elisabeth, Meyer, Ina, Arzt, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673191/
https://www.ncbi.nlm.nih.gov/pubmed/36401172
http://dx.doi.org/10.1186/s10194-022-01515-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673191/
https://www.ncbi.nlm.nih.gov/pubmed/36401172
http://dx.doi.org/10.1186/s10194-022-01515-8

Ejemplares similares